Earnings
It’s been a bumpy ride for Biogen as news swirls around its overall Alzheimer’s program… but not for its competitors with investigational therapies for that disease.
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
Halozyme revealed that ViiV will pay $40 million upfront for the exclusive license to four small and large molecule targets and then pay the remaining $175 million in milestones.
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
Shares of iTeos Therapeutics skyrocketed more than 50% in premarket trading after it struck an agreement with GSM to co-develop and commercialize a cancer treatment.
Two of the company’s largest shareholders call for the ouster of a company director at Regeneron as top executives are under fire for their enormous compensation packages.
June appears to be a busy month for Series A financing rounds, with Kurome, Onchilles Pharma, and Hawthorne Effect closing in on millions of dollars worth of startup investments.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
PRESS RELEASES